Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 17;43(1):230.
doi: 10.1186/s13046-024-03132-6.

tsRNA-GlyGCC promotes colorectal cancer progression and 5-FU resistance by regulating SPIB

Affiliations

tsRNA-GlyGCC promotes colorectal cancer progression and 5-FU resistance by regulating SPIB

Rong Xu et al. J Exp Clin Cancer Res. .

Abstract

Background: tRNA-derived small RNAs (tsRNAs) are newly discovered non-coding RNA, which are generated from tRNAs and are reported to participate in several biological processes in diseases, especially cancer; however, the mechanism of tsRNA involvement in colorectal cancer (CRC) and 5-fluorouracil (5-FU) is still unclear.

Methods: RNA sequencing was performed to identify differential expression of tsRNAs in CRC tissues. CCK8, colony formation, transwell assays, and tumor sphere assays were used to investigate the role of tsRNA-GlyGCC in 5-FU resistance in CRC. TargetScan and miRanda were used to identify the target genes of tsRNA-GlyGCC. Biotin pull-down, RNA pull-down, luciferase assay, ChIP, and western blotting were used to explore the underlying molecular mechanisms of action of tsRNA-GlyGCC. The MeRIP assay was used to investigate the N(7)-methylguanosine RNA modification of tsRNA-GlyGCC.

Results: In this study, we uncovered the feature of tsRNAs in human CRC tissues and confirmed a specific 5' half tRNA, 5'tiRNA-Gly-GCC (tsRNA-GlyGCC), which is upregulated in CRC tissues and modulated by METTL1-mediated N(7)-methylguanosine tRNA modification. In vitro and in vivo experiments revealed the oncogenic role of tsRNA-GlyGCC in 5-FU drug resistance in CRC. Remarkably, our results showed that tsRNA-GlyGCC modulated the JAK1/STAT6 signaling pathway by targeting SPIB. Poly (β-amino esters) were synthesized to assist the delivery of 5-FU and tsRNA-GlyGCC inhibitor, which effectively inhibited tumor growth and enhanced CRC sensitive to 5-FU without obvious adverse effects in subcutaneous tumor.

Conclusions: Our study revealed a specific tsRNA-GlyGCC-engaged pathway in CRC progression. Targeting tsRNA-GlyGCC in combination with 5-FU may provide a promising nanotherapeutic strategy for the treatment of 5-FU-resistance CRC.

Keywords: 5-FU resistance; CRC; JAK1/STAT6; METTL1; SPIB; m7G; tsRNA.

PubMed Disclaimer

Conflict of interest statement

All the authors declare no conflicts of interest.

Figures

Fig. 1
Fig. 1
tsRNA-GlyGCC is overexpressed in CRC tissues. A-C. The difference of tsRNA profiles, volcano plot and heat map displaying differentially expressed tsRNA between five pairs of CRC and corresponding normal tissues; D. tsRNA-GlyGCC was significantly upregulation in CRC tissues; E. The structure of tRNA; F. tsRNA-GlyGCC was originated from tRNA-Gly-GCC; G. tsRNA-GlyGCC was mainly located in cell cytoplasm; H. The product of tsRNA-GlyGCC was confirmed by Sanger Sequencing; I. tsRNA-GlyGCC was located in cell cytoplasm by using IF assay; J. FISH assay was used for tsRNA-GlyGCC detection; K. qPCR was conducted to examine the expression of tsRNA-GlyGCC in normal, response CRC, and non-response CRC tissues, *p < 0.05, **p < 0.01, ***p < 0.01. All data are representative of at least three independent experiments and are presented as the means ± SD
Fig. 2
Fig. 2
tsRNA-GlyGCC promote cell proliferation and reduce cell apoptosis in CRC. A.The tsRNA-GlyGCC inhibitor significantly decrease cell proliferation, while tsRNA-GlyGCC mimics promote cell reproductive capacity; B-D. tsRNA-GlyGCC inhibitor reduced anchorage-dependent growth in 5-FU resistance CRC cells; E-G. tsRNA-GlyGCC inhibitor reduced cell migration using transwell assays; H-J. tsRNA-GlyGCC inhibitor induced apoptosis using FACS analysis. K-M. tsRNA-GlyGCC inhibitor decreased the growth of cell spheroids. *p < 0.05, **p < 0.01, ***p < 0.01. All data are representative of at least three independent experiments and are presented as the means ± SD
Fig. 3
Fig. 3
tsRNA-GlyGCC plays an oncogenic role in vivo. A. Flow chart of animal experiment; B. Body weight of mice in different groups; C. Representative photos of tumours; D: Tumor growth measured using a line chart; E. Tumor weights in different groups; F. Tunnel assay was used to detect cell apoptosis in different groups; G. Protein level of Ki67 in tumor tissues in different groups. *p < 0.05, **p < 0.01. All data are representative of at least three independent experiments and are presented as the means ± SD
Fig. 4
Fig. 4
tsRNA-GlyGCC directly targets SPIB. A. Identification of potential target genes of tsRNA-GlyGCC; B-C. The mRNA expression in cells transfected with tsRNA-GlyGCC mimics; D. The mRNA level of SPIB in CRC and adjacent normal tissues; E. Correlation analysis between SPIB and tsRNA-GlyGCC; F. The binding site between SPIB and tsRNA-GlyGCC; G. Luciferase assay was used to check the luciferase activity of wide type and mut type groups; H-I. WB assay was used to detect the protein level of SPIB when transfected with tsRNA-GlyGCC inhibitor. *p < 0.05, **p < 0.01. All data are representative of at least three independent experiments and are presented as the means ± SD
Fig. 5
Fig. 5
SPIB is a transcriptional repressor of STAT6. A-B. WB assay was used to detect the protein level of JAK1/STAT6; C. The binding sites of SPIB in STAT6 promoter region by using JASPAR database; D. Schematic diagrams of promoters of STAT6; E-F. ChIP assay was used to verify that SPIB could bind to STAT6 promoter region; G. Construction dual-luciferase reporter plasmids based on the binding sites of SPIB; H. Luciferase assay was used to detect luciferase activity in HCT116 cells overexpressing SPIB after transfection of pGL enhancer plasmids containing wide type or mut type STAT6 promoter. *p < 0.05, **p < 0.01, ***p < 0.001. All data are representative of at least three independent experiments and are presented as the means ± SD
Fig. 6
Fig. 6
m7G modification on tsRNA-GlyGCC. A.The schematic diagram of m7G-MeRIP assay; B. m7G-MeRIP assay was performed to verification of m7G modification sites; C-D. The expression of METTL1 in CRC tissues; E. Interference efficiency of METTL1 by using sh-plasmid; F. tsRNA-GlyGCC was downexpressed in CRC cells transfected with sh-METTL1-1 and sh-METTL1-2; G. Interference with METTL1 expression could reduce the sequencing which containing site 29 enrichment. **p < 0.01, ***p < 0.001. All data are representative of at least three independent experiments and are presented as the means ± SD
Fig. 7
Fig. 7
Characterization of PAE@5−FUts-inhibitor complex. A.TEM images of PAE@5−FUts-inhibitor complex; B. Particle size of the PAE@5−FUts-inhibitor complex; C. Zeta potential of PAE and PAE@5−FUts-inhibitor; D. Biodistribution of PAE@5−FUts-inhibitor; E. Stability analysis of PAE@5−FUts-inhibitor; F. The expression of tsRNA-GlyGCC.**p < 0.01, ***p < 0.001. All data are representative of at least three independent experiments and are presented as the means ± SD
Fig. 8
Fig. 8
The antitumor effects of PAE@5−FUts-inhibitor in vivo. A.The schematic diagram of mice treatment; B. Representative photos of tumours; C-D. The tumor volume and weight in different groups; E. HE staining of tumour cells in different groups; F. FISH assay was conducted to detect the expression of tsRNA-GlyGCC in different groups; G. Immunofluorescence staining was used to detect Ki67 expression in different groups; H-I. IHC was used to detected the expression of SPIB (H) and STAT6 (I) in tumor tissues; J-K.Tunnel assay was used to apoptosis in different groups; **p < 0.01, ***p < 0.001. All data are representative of at least three independent experiments and are presented as the means ± SD

References

    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. 10.3322/caac.21660 - DOI - PubMed
    1. Di Y, Jing X, Hu K, Wen X, Ye L, Zhang X, Qin J, Ye J, Lin R, Wang Z, He W. The c-MYC-WDR43 signalling axis promotes chemoresistance and tumour growth in colorectal cancer by inhibiting p53 activity. Drug Resist Updat. 2023;66:100909. 10.1016/j.drup.2022.100909 - DOI - PubMed
    1. Jiang Z, Zou Q, Chen Q, Zhang J, Tang H, Chen J, Qin Y, Yang L, Chen Z, Cao L. Therapeutic role of Wuda granule in gastrointestinal motility disorder through promoting gastrointestinal motility and decreasing inflammatory level. Front Pharmacol. 2023;14:1237686. 10.3389/fphar.2023.1237686 - DOI - PMC - PubMed
    1. Pita-Fernandez S, Alhayek-Ai M, Gonzalez-Martin C, Lopez-Calvino B, Seoane-Pillado T, Pertega-Diaz S. Intensive follow-up strategies improve outcomes in nonmetastatic colorectal cancer patients after curative surgery: a systematic review and meta-analysis. Ann Oncol. 2015;26:644–56. 10.1093/annonc/mdu543 - DOI - PubMed
    1. Xu Y, Liu K, Li C, Li M, Liu F, Zhou X, Sun M, Ranganathan M, Zhang L, Wang S, Hu X, Xu Y. The largest Chinese cohort study indicates homologous recombination pathway gene mutations as another major genetic risk factor for colorectal Cancer with heterogeneous clinical phenotypes. Research (Wash D C) 2023; 6: 0249. - PMC - PubMed